Antimicrobial resistance

Biotechnology Company Centivax Officially Launches

Retrieved on: 
Thursday, April 29, 2021
Health sciences, Health, Articles, Broad-spectrum therapeutic, Drugs, Vaccine, Antimicrobial resistance

is proud to announce its launch on Jan. 1, 2021, as a fully independent biotechnology company developing broad-spectrum therapeutics and avaccines portfolio, including indications in COVID-19, multi-drug resistant bacteria, influenza, antivenom and oncology.

Key Points: 
  • is proud to announce its launch on Jan. 1, 2021, as a fully independent biotechnology company developing broad-spectrum therapeutics and avaccines portfolio, including indications in COVID-19, multi-drug resistant bacteria, influenza, antivenom and oncology.
  • "Our unusually mature portfolio of fully owned Centivax assets has been made possible by advanced computationalimmunoengineeringtechnology platforms and intellectual property that enable Centivax to rapidly create the broad-spectrum antibodies and broad-spectrum vaccines clearly needed in 21st-century medicine," says Dr. Jacob Glanville, Founder and CEO of Centivax.
  • "It is these platforms that enable Centivax to enter clinical development of our first therapeutic within eight months oflaunch.
  • Dr. Nicholas Bayless, PhD, Co-founder of Centivax and Director of Translational Strategy, has several years of experience in advanced clinical trial design.

Specific Diagnostics Awarded Grant by the Department of Defense (DoD) to use Reveal for the Rapid Determination of the Antimicrobial Effectiveness of Bacteriophage

Retrieved on: 
Thursday, April 29, 2021
Public policy, Government, Health, Healthcare reform, Infectious diseases, Other Policy Issues, Pharmaceutical, Biotechnology, Health sciences, Health, Articles, Pharmaceuticals policy, Veterinary medicine, Antimicrobial resistance, Evolutionary biology, Drug resistance, Phage therapy, Antibiotic, Bacteriophage

With bacteria evolving resistance to antibiotics, driven in part by overuse, bacteriophage therapy represents a distinct and promising alternative to antibiotic therapy.\n\xe2\x80\x9cIn the age of antibiotic resistance, alternatives to antibiotics are increasingly needed,\xe2\x80\x9d said Dr. Paul A. Rhodes, Specific\xe2\x80\x99s CEO.

Key Points: 
  • With bacteria evolving resistance to antibiotics, driven in part by overuse, bacteriophage therapy represents a distinct and promising alternative to antibiotic therapy.\n\xe2\x80\x9cIn the age of antibiotic resistance, alternatives to antibiotics are increasingly needed,\xe2\x80\x9d said Dr. Paul A. Rhodes, Specific\xe2\x80\x99s CEO.
  • Its first commercial application applies this fundamental new capability to the rapid determination of antimicrobial susceptibility directly from positive blood cultures, as well as isolate dilutions.
  • Specific is based in Mountain View, CA.
  • For press inquiries, please contact: Jeff Holman, [email protected]\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210429005732/en/\n'

New PhRMA Report Shows Nearly 90 Medicines in Development to Fight Drug-Resistant Infections, but Future Pipeline Remains Challenging

Retrieved on: 
Thursday, April 29, 2021
Health sciences, Articles, Pharmaceuticals policy, Life sciences, Veterinary medicine, Evolutionary biology, Antimicrobial resistance, Antimicrobial, Antibiotic, Medication

Today, this progress is being threatened by a health crisis on the rise: antimicrobial resistance (AMR).

Key Points: 
  • Today, this progress is being threatened by a health crisis on the rise: antimicrobial resistance (AMR).
  • Developing new antimicrobial medicines can take anywhere from 10-20.5 years and $568-$700 million to develop a single new medicine.
  • In fact, among investigational medicines in preclinical development for existing classes of antibiotics just one in 15 will ultimately be approved and reach patients.
  • Those new treatments could be the ones we need to address the next pandemic, or the next superbug.

X-Biotix Therapeutics Announces Change in Corporate Strategy

Retrieved on: 
Monday, April 26, 2021
Health, Infectious diseases, Research, Pharmaceutical, Science, Biotechnology, Branches of biology, Health sciences, Medical specialties, Antibiotics, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Bacteriology, Antimicrobial resistance, Drug resistance, Bacteria, Multiple drug resistance

b'X-Biotix Therapeutics, Inc. (X-Biotix), a biotechnology company focused on the discovery and development of first-in-class antibiotic compounds targeting multi-drug-resistant Gram-negative pathogens, announced today a change in its strategy, which will include suspension of its current antibacterial research efforts.

Key Points: 
  • b'X-Biotix Therapeutics, Inc. (X-Biotix), a biotechnology company focused on the discovery and development of first-in-class antibiotic compounds targeting multi-drug-resistant Gram-negative pathogens, announced today a change in its strategy, which will include suspension of its current antibacterial research efforts.
  • Resistant infections cost the US $20B in excess healthcare costs and $35B in lost productivity.
  • Co-founders of the company include distinguished faculty from Harvard Medical School, with expertise in biological mechanisms of cell envelope biosynthesis, antibiotic resistance and efflux.
  • For further information, please visit: http://www.x-biotixrx.com/\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210426005029/en/\n'

Seventy-one scholars from 13 countries attended the 27th International Science Conference

Retrieved on: 
Monday, April 26, 2021
Articles, Chemistry, Matter, Refractory materials, Graphite, Carbon, Earth Day, Antimicrobial resistance

b"Easing global problems like deforestation, desertification and the rise of antibiotic-resistant bacteria will have profound benefits for humanity, speakers told a recent two-day virtual science conference.\nSeventy-one scholars from 13 countries attended ICUS XXVII, which was held online on April 23-24, 2021 EDT.

Key Points: 
  • b"Easing global problems like deforestation, desertification and the rise of antibiotic-resistant bacteria will have profound benefits for humanity, speakers told a recent two-day virtual science conference.\nSeventy-one scholars from 13 countries attended ICUS XXVII, which was held online on April 23-24, 2021 EDT.
  • New strategies are already being examined to boost the power of these batteries while keeping costs down, he said.
  • Perhaps a new formulation, which uses graphite-silicon composite, is needed, responded Dr. Byung-Gwan Lee, research director of Eurocell Inc., in South Korea.\nAt the conference closing, Dr. Joo announced that HJIFUS launched an environmental periodical, The Earth & I, on April 22, Earth Day, which can be freely viewed at theearthandi.org.
  • Besides covering environmental news and issues, The Earth & I will offer policy proposals and serve as a resource for educators and the general public.\n"

OpGen Extends and Expands Partnership with New York State Department of Health to Detect Antimicrobial-Resistant Infections

Retrieved on: 
Monday, April 19, 2021
Articles, Health sciences, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, XC2, Antimicrobial resistance, Antimicrobial, Life sciences, Antibiotic

\xe2\x80\x9cThe quick spread of antimicrobial resistant superbugs across healthcare systems is the silent pandemic hidden underneath the current COVID-19 pandemic.

Key Points: 
  • \xe2\x80\x9cThe quick spread of antimicrobial resistant superbugs across healthcare systems is the silent pandemic hidden underneath the current COVID-19 pandemic.
  • Together, these products can help to rapidly identify and locate antibiotic resistance threats in healthcare institutions and networks.
  • Victory Derbyshire\xc2\xa0said,\xc2\xa0\xe2\x80\x9cUnder Governor Cuomo\'s leadership New York State\xc2\xa0continues to lead the nation in addressing the threat of antimicrobial resistance.
  • The Center serves a vital role in the\xc2\xa0New York State Department\xc2\xa0of Health\xe2\x80\x99s efforts to protect and promote the health of New York\xe2\x80\x99s citizens.

Phico Therapeutics Awarded up to $18.2 Million USD (c.£13.2 Million GBP) CARB-X Funding to Advance SASPject Antibacterial Therapy Through Phase 1 Clinical Trials

Retrieved on: 
Monday, April 19, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Hospitals, Clinical trials, Health sciences, Medical specialties, Medicine, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Antimicrobial resistance, Drug resistance, XC2, Antibiotic, Bacteria

\xc2\xa313.2 million GBP) from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.

Key Points: 
  • \xc2\xa313.2 million GBP) from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
  • The funding will support the progression of Phico\xe2\x80\x99s lead product SASPject\xe2\x84\xa2 PT3.9 through clinical trials with $5.3 million USD (circa.
  • \xc2\xa33.8 million GBP) available immediately and a further $12.9 million (circa.
  • Heather Fairhead, Phico Founder and CEO said: \xe2\x80\x9cTo receive funding from CARB-X is important validation for our SASPject technology platform and its potential in fighting bacterial resistance.

Hologic to Acquire Mobidiag, Innovator in Near-Patient, Acute Care Diagnostic Testing, for Approximately $795 Million

Retrieved on: 
Thursday, April 8, 2021
Technology, Medical devices, Women, Software, Biotechnology, Health, Consumer, General Health, Data management, Articles, Life sciences, Branches of biology, Infectious diseases, Amplifiers, Biotechnology, Molecular biology, Polymerase chain reaction, Respiratory tract infection, Antimicrobial resistance, Infection

This includes a cash payment of approximately $714 million (600 million) for Mobidiags equity, and net debt of approximately $81 million.

Key Points: 
  • This includes a cash payment of approximately $714 million (600 million) for Mobidiags equity, and net debt of approximately $81 million.
  • Mobidiag develops and markets PCR (polymerase chain reaction)-based tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare associated infections.
  • The Amplidiag and Novodiag platforms are automated instruments that deliver rapid turnaround times ranging from 50 minutes to two hours.
  • Mobidiag generated approximately $42 million (35 million) of revenue in calendar 2020.

A new report finds waterways near industrial farms in Canada could be a public health threat

Retrieved on: 
Wednesday, April 7, 2021
Articles, Livestock, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Health sciences, Medicine, Antimicrobial resistance, Caesarean section, Pig farming

TORONTO, April 7, 2021 /CNW/ - Public waterways next to industrial farms in Manitoba contain antibiotic resistance genes (ARGs) that are dangerous to public health says a report from the global charity World Animal Protection.

Key Points: 
  • TORONTO, April 7, 2021 /CNW/ - Public waterways next to industrial farms in Manitoba contain antibiotic resistance genes (ARGs) that are dangerous to public health says a report from the global charity World Animal Protection.
  • If action is not taken, in future, routine procedures like caesarean sections or cancer treatments could become dangerous worldwide.
  • The report found that industrial farms could be discharging superbugs into the wider environment as a result of pig waste being spread on fields and leeching into groundwater and public waterways.
  • In Manitoba, the presence of ARGs was evaluated from samples collected in November 2020 from publicly accessible spaces upstream and downstream of eight industrial pig farms.

Cūrza and the University of Florida Expand Collaboration to Include Bacterial Biothreats with DTRA Award

Retrieved on: 
Thursday, April 1, 2021
Health sciences, Medicine, Health, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Immunology, Antibiotic, Antimicrobial resistance, Defense Threat Reduction Agency, Drug resistance

SALT LAKE CITY, April 1, 2021 /PRNewswire/ --Crza Global, LLC (Crza) announced today that The Institute for Therapeutic Innovation (ITI) at the University of Florida has been awarded a $75M contract from the Defense Threat Reduction Agency (DTRA) in partnership with Crza.

Key Points: 
  • SALT LAKE CITY, April 1, 2021 /PRNewswire/ --Crza Global, LLC (Crza) announced today that The Institute for Therapeutic Innovation (ITI) at the University of Florida has been awarded a $75M contract from the Defense Threat Reduction Agency (DTRA) in partnership with Crza.
  • This program is aimed at the development of Crza's CZ-02 platform of antibiotics for the treatment of drug-resistant bacterial infections.
  • The CZ-02 platform represents a novel class of antibacterial agents with a unique mode of action.
  • Chad Testa, Ph.D., Vice President of Research at Crza will serve as Principal Investigator (PI) for Crza.